The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
Open accessAbstract
Background The triplet FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab showed improved outcomes for patients with metastatic colorectal cancer, compared with FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus bevacizumab. However, the actual benefit of the upfront exposure to the three cytotoxic drugs compared with a preplanned sequential strategy of doublets was not clear, and neither was the feasibility or efficacy of therapies after disease progression. We aimed to compare a preplanned strategy of upfront FOLFOXIRI followed by the reintroduction of the same regimen after disease progression versus a sequence of mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) and FOLFIRI doublets, in combination with bevacizumab.Methods TRIBE2 was an open-label, phase 3, randomised study of patients aged 18-75 years with an Eastern Cooperative Oncology Group (ECOG) performance status of 2, with unresectable, previously untreated metastatic colorectal cancer, recruited from 58 Italian oncology units. Patients were stratified according to centre, ECOG performance status, primary tumour location, and previous adjuvant chemotherapy. A randomisation system incorporating a minimisation algorithm was used to randomly assign patients (1:1) via a masked web-based allocation procedure to two different treatment strategies. In the control group, patients received first-line mFOLFOX6 (85 mg/m 2 of intravenous oxaliplatin concurrently with 200 mg/m 2 of leucovorin over 120 min; 400 mg/m 2 intravenous bolus of fluorouracil; 2400 mg/m 2 continuous infusion of fluorouracil for 48 h) plus bevacizumab (5 mg/kg intravenously over 30 min) followed by FOLFIRI (180 mg/m 2 of intravenous irinotecan over 120 min concurrently with 200 mg/m 2 of leucovorin; 400 mg/m 2 intravenous bolus of fluorouracil; 2400 mg/m 2 continuous infusion of fluorouracil for 48 h) plus bevacizumab after disease progression. In the experimental group, patients received FOLFOXIRI (165 mg/m 2 of intravenous irinotecan over 60 min; 85 mg/m 2 intravenous oxaliplatin concurrently with 200 mg/m 2 of leucovorin over 120 min; 3200 mg/m 2 continuous infusion of fluorouracil for 48 h) plus bevacizumab followed by the reintroduction of the same regimen after disease progression. Combination treatments were repeated every 14 days for up to eight cycles followed by fluorouracil and leucovorin (at the same dose administered at the last induction cycle) plus bevacizumab maintenance until disease progression, unacceptable adverse events, or consent withdrawal. Patients and investigators were not masked. The primary endpoint was progression-free survival 2, defined as the time from randomisation to disease progression on any treatment given after first disease progression, or death, analysed by intention to treat. Safety was assessed in patients who received at least one dose of their assigned treatment. Study recruitment is complete and follow-up is ongoing. This trial is registered with Clinicaltrials.gov, NCT02339116.Findings Between Feb 26, 2015, and May 15, 2017, 679 patients were randomly assigned and received treatment (340 in the control group and 339 in the experimental group). At data cut-off (July 30, 2019) median follow-up was 35·9 months (IQR 30·1-41·4). Median progression-free survival 2 was 19·2 months (95% CI 17·3-21·4) in the experimental group and 16·4 months (15·1-17·5) in the control group (hazard ratio [HR] 0·74, 95% CI 0·63-0·88; p=0·0005). During the first-line treatment, the most frequent of all-cause grade 3-4 events were diarrhoea (57 [17%] vs 18 [5%]), neutropenia (168 [50%] vs 71 [21%]), and arterial hypertension (25 [7%] vs 35 [10%]) in the experimental group compared with the control group. Serious adverse events occurred in 84 (25%) patients in the experimental group and in 56 (17%) patients in the control group. Eight treatment-related deaths were reported in the experimental group (two intestinal occlusions, two intestinal perforations, two sepsis, one myocardial infarction, and one bleeding) and four in the control group (two occlusions, one perforation, and one pulmonary embolism). After first disease progression, no substantial differences in the incidence of grade 3 or 4 adverse events were reported between the control and experimental groups, with the exception of neurotoxicity, which was only reported in the experimental group (six [5%] of 132 patients). Serious adverse events after disease progression occurred in 20 (15%) patients in the experimental group and 25 (12%) in the control group. Three treatment-related deaths after first disease progression were reported in the experimental group (two intestinal occlusions and one sepsis) and four in the control group (one intestinal occlusion, one intestinal perforation, one cerebrovascular event, and one sepsis).Interpretation Upfront FOLFOXIRI plus bevacizumab followed by the reintroduction of the same regimen after disease progression seems to be a preferable therapeutic strategy to sequential administration of chemotherapy doublets, in combination with bevacizumab, for patients with metastatic colorectal cancer selected according to the study criteria.Funding The GONO Cooperative Group, the ARCO Foundation, and F Hoffmann-La Roche.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The results showed a significant advantage for upfront FOLFOXIRI plus bevacizumab in terms of PFS2 with an mPFS2 of 19.1 months vs. 16.4 months for the comparator arm (HR 0.74, p < 0.001).”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Self-citationPanitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Cederquist, L., Chan, E., Chen, Y., Cooper, H. S., Deming, D. A., Engstrom, P. F., Enzinger, P. C., Fichera, A., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0036 · Cited by 1,333
Bennouna, J., Sastre, J., Arnold, D., Österlund, P., Greil, R., Van Cutsem, E., von Moos, R., Viéitez, J. M., Bouché, O., Borg, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70477-1 · Cited by 1,166
Cremolini, C., Loupakis, F., Antoniotti, C., Lupi, C., Sensi, E., Lonardi, S., Mezi, S., Tomasello, G., Ronzoni, M., Zaniboni, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00122-9 · Cited by 1,092
Self-citationInitial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Loupakis, F., Cremolini, C., Masi, G., Lonardi, S., Zagonel, V., Salvatore, L., Cortesi, E., Tomasello, G., Ronzoni, M., Spadi, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403108 · Cited by 1,062
Self-citationVan Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4812 · Cited by 789
Self-citationSimkens, L. H. J., van Tinteren, H., May, A. M., ten Tije, A. J., Creemers, G., Loosveld, O. J. L., de Jongh, F. E., Erdkamp, F., Erjavec, Z., van der Torren, A. M. E., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62004-3 · Cited by 526
Stintzing, S., Modest, D. P., Rossius, L., Lerch, M. M., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30269-8 · Cited by 420
Cited by
Sorted by citations
Diagnosis and Treatment of Metastatic Colorectal Cancer
Biller, L. H., & Schrag, D. (2021) · JAMA · doi:10.1001/jama.2021.0106 · Cited by 2,708
Cervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y., Ciombor, K. K., Cohen, S. A., Cooper, H. S., Deming, D. A., Farkas, L. M., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0012 · Cited by 1,737
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
Morris, V. K., Kennedy, E. B., Baxter, N. N., Benson, A. B., Cercek, A., Cho, M., Ciombor, K. K., Cremolini, C., Davis, A., Deming, D. A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01690 · Cited by 682
Self-citationVernieri, C., Fucà, G., Ligorio, F., Huber, V., Vingiani, A., Iannelli, F., Raimondi, A., Rinchai, D., Frigè, G., Belfiore, A., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0030 · Cited by 319
Colorectal liver metastasis: molecular mechanism and interventional therapy
Zhou, H., Liu, Z., Wang, Y., Wen, X., Amador, E. H., Yuan, L., Ran, X., Xiong, L., Ran, Y., Chen, W., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00922-2 · Cited by 298
Antoniotti, C., Rossini, D., Pietrantonio, F., Catteau, A., Salvatore, L., Lonardi, S., Boquet, I., Tamberi, S., Marmorino, F., Moretto, R., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00274-1 · Cited by 280
Self-citationCremolini, C., Antoniotti, C., Stein, A., Bendell, J. C., Gruenberger, T., Rossini, D., Masi, G., Ongaro, E., Hurwitz, H. I., Falcone, A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01225 · Cited by 241
Self-citationGrothey, A. F., Fakih, M., & Tabernero, J. M. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.206 · Cited by 220
Adam, R. A., Piedvache, C., Chiche, L., Adam, J. P., Salamé, E., Bucur, P. O., Cherqui, D., Scatton, O., Granger, V., Ducreux, M. P., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01595-2 · Cited by 196
Self-citationSurvival improvement for patients with metastatic colorectal cancer over twenty years
Zeineddine, F. A., Zeineddine, M. A., Yousef, A., Gu, Y., Chowdhury, S., Dasari, A., Huey, R. W., Johnson, B., Kee, B., Lee, M. S., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00353-4 · Cited by 192
The Colorectal Cancer Tumor Microenvironment and Its Impact on Liver and Lung Metastasis
Chandra, R., Karalis, J. D., Liu, C., Murimwa, G. Z., Park, J. V., Heid, C. A., Reznik, S. I., Huang, E. H., Minna, J. D., & Brekken, R. A. (2021) · Cancers · doi:10.3390/cancers13246206 · Cited by 168
PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies
Lin, K. X., Istl, A. C., Quan, D., Skaro, A. I., Tang, E. S.-T., & Zheng, X. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03520-5 · Cited by 172
Mulcahy, M. F., Mahvash, A., Pracht, M., Montazeri, A. H., Bandula, S., Martin, R. C. G., Herrmann, K., Brown, E., Zuckerman, D., Wilson, G., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01839 · Cited by 156
Dual Inhibition of DKC1 and MEK1/2 Synergistically Restrains the Growth of Colorectal Cancer Cells
Kan, G., Wang, Z., Sheng, C., Gong, C., Yao, C., Mao, Y., & Chen, S. (2021) · Advanced Science · doi:10.1002/advs.202004344 · Cited by 95
Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
Chiorean, E. G., Chiaro, M. D., Tempero, M. A., Malafa, M. P., Benson, A. B., Cardin, D. B., Christensen, J. A., Chung, V. M., Czito, B. G., Dillhoff, M. E., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0034 · Cited by 102
Advances in the management of peritoneal malignancies
Képénékian, V., Bhatt, A., Péron, J., Alyami, M. S., Benzerdjeb, N., Bakrin, N., Falandry, C., Passot, G., Rousset, P., & Gléhen, O. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00675-5 · Cited by 87
Guo, L., Wang, Y., Yang, W., Wang, C., Guo, T., Yang, J., Shao, Z., Cai, G., Cai, S., Zhang, L., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.04.029 · Cited by 85
Antoniotti, C., Borelli, B., Rossini, D., Pietrantonio, F., Morano, F., Salvatore, L., Lonardi, S., Marmorino, F., Tamberi, S., Corallo, S., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07169-6 · Cited by 82
Self-citationKinugasa, Y., Uehara, K., Yamaguchi, K., Saito, Y., Murofushi, K. N., Sugai, T., Ishiguro, M., Ishihara, S., Ueno, H., Oka, S., et al. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02899-8 · Cited by 99
Moretto, R., Elliott, A., Zhang, J., Arai, H., Germani, M. M., Conca, V., Xiu, J., Stafford, P., Oberley, M. J., Abraham, J. P., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab169 · Cited by 77
Self-citationMauri, G., Gori, V., Bonazzina, E. F., Amatu, A., Tosi, F., Bencardino, K. B., Ruggieri, L., Patelli, G., Arena, S., Bardelli, A., et al. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102112 · Cited by 80
The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer
Mauri, G., Bonazzina, E., Amatu, A., Tosi, F., Bencardino, K., Gori, V., Massihnia, D., Cipani, T., Spina, F., Ghezzi, S., et al. (2021) · Cancers · doi:10.3390/cancers13010137 · Cited by 73
Cremolini, C., Chalabi, M., Élez, E., Fassan, M., Gelli, M., Goèré, D., Modest, D. P., Viladot, C. M., Osterlund, P. J., Ricke, J., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.03.005 · Cited by 89
Self-citationStintzing, S., Heinrich, K., Tougeron, D., Modest, D. P., Schwaner, I., Eucker, J., Pihusch, R., Stauch, M. B., Kaiser, F., Kahl, C., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01420 · Cited by 73
The Evolving Treatment Landscape in BRAF-V600E –Mutated Metastatic Colorectal Cancer
Tabernero, J. M., Ros, J., & Élez, E. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349561 · Cited by 71
Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease
Aparicio, J., Esposito, F. M., Serrano, S., Falcó, E., Escudero, P., Ruiz‐Casado, A., Manzano, H., & Montés, A. F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123889 · Cited by 71
Abraham, J. P., Magee, D., Cremolini, C., Antoniotti, C., Halbert, D. D., Xiu, J., Stafford, P., Berry, D. A., Oberley, M. J., Shields, A. F., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3286 · Cited by 67
Self-citationPrognostic and Predictive Molecular Biomarkers in Advanced Colorectal Cancer
Martelli, V., Pastorino, A., & Sobrero, A. F. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108239 · Cited by 63
Self-citationBRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
Ros, J., Baraibar, I., Sardo, E., Mulet-Margalef, N., Salvà, F., Argilés, G., Martini, G., Ciardiello, D., Cuadra‐Urteaga, J. L., Tabernero, J. M., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835921992974 · Cited by 68
Giunta, E. F., Bregni, G., Pretta, A., Deleporte, A., Liberale, G., Bali, A. M., Moretti, L., Troiani, T., Ciardiello, F., Hendlisz, A., et al. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102177 · Cited by 67
Self-citationShroff, R. T., King, G. T., Colby, S., Scott, A. J., Borad, M. J., Goff, L. W., Matin, K., Mahipal, A., Kalyan, A., Javle, M. M., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco-24-01383 · Cited by 60
Aranda, E., Viéitez, J. M., Gómez‐España, A., Calle, S. G., Salud, A., Graña, B., Alfonso, P. G., Rivera, F., Aldana, G. Q., Zoilo, J. J. R., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000944 · Cited by 59
Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge
Marmorino, F., Boccaccino, A., Germani, M. M., Falcone, A., & Cremolini, C. (2020) · Cancers · doi:10.3390/cancers12082317 · Cited by 58
Self-citationThe Role of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer
Body, A. L., Prenen, H., Latham, S., Lam, M., Tipping-Smith, S., Raghunath, A., & Segelov, E. (2021) · Cancer Management and Research · doi:10.2147/cmar.s262870 · Cited by 58
Precision medicine for metastatic colorectal cancer in clinical practice
Riedesser, J. E., Ebert, M. P. A., & Betge, J. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211072703 · Cited by 58
Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments
Tang, Y., Li, D., Duan, J.-Y., Sheng, L., & Wang, X. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i6.926 · Cited by 58
Cheng, F., Zhang, R., Sun, C., Ran, Q., Zhang, C., Shen, C., Yao, Z., Wang, M., Song, L., & Peng, C. Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1231401 · Cited by 56
Patel, R. K., Rahman, S., Schwantes, I. R., Bartlett, A. Q., Eil, R. L., Farsad, K., Fowler, K. J., Goodyear, S. M., Hansen, L., Kardosh, A., et al. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.08.012 · Cited by 55
Obesity-Associated Colorectal Cancer
Gonzalez-Gutierrez, L., Motiño, O., Barriuso, D., de la Puente-Aldea, J., Alvarez-Frutos, L., Kroemer, G., Palacios, R., & Senovilla, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168836 · Cited by 54
Peritoneal Metastasis: Current Status and Treatment Options
Roth, L., Russo, L. A., Ulugöl, S., dos Santos, R. F., Breuer, E., Gupta, A. K., & Lehmann, K. (2021) · Cancers · doi:10.3390/cancers14010060 · Cited by 52
Moretto, R., Rossini, D., Catteau, A., Antoniotti, C., Giordano, M., Boccaccino, A., Ugolini, C., Proietti, A., Conca, V., Kassambara, A., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006633 · Cited by 46
Self-citationHe, R., Lao, Y., Yu, W., Zhang, X., Jiang, M., & Zhu, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.764618 · Cited by 46
The effective combination therapies with irinotecan for colorectal cancer
Chai, Y., Liu, J., Zhang, S., Li, N., Xu, D., Liu, W., Fu, R., & Tang, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1356708 · Cited by 51
Low-dose orlistat promotes the therapeutic effect of oxaliplatin in colorectal cancer
Zhang, Q. H., Zhou, Y., Feng, X., Gao, Y., Huang, C., & Yao, X. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113426 · Cited by 41
Metastasis organotropism in colorectal cancer: advancing toward innovative therapies
He, K., Wang, Z., Luo, M., Li, B., Ding, N., Li, L., He, B., Wang, H., Cao, J., Huang, C., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04460-5 · Cited by 45
Ciracì, P., Studiale, V., Taravella, A., Antoniotti, C., & Cremolini, C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00965-0 · Cited by 47
Self-citationManzi, J. L. L., Hoff, C. O., Ferreira, R., Pimentel, A., Datta, J., Livingstone, A. S., Vianna, R., & Abreu, P. (2023) · Cancers · doi:10.3390/cancers15113023 · Cited by 41
Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer
Lai, E., Liscia, N., Donisi, C., Mariani, S., Tolu, S., Pretta, A., Persano, M., Pinna, G., Balconi, F., Pireddu, A., et al. (2020) · Cancers · doi:10.3390/cancers12051214 · Cited by 37
Innominato, P. F., Karaboué, A., Focan, C., Chollet, P. J. M., Giacchetti, S., Bouchahda, M., Ulusakarya, A., Torsello, A., Adam, R. A., Lévi, F., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33422 · Cited by 37
Martinelli, E., Cremolini, C., Mazard, T., Vidal, J., Virchow, I., Tougeron, D., Cuyle, P., Chibaudel, B., Kim, S. C. H., Ghanem, I., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100603 · Cited by 38
Self-citationFirst-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases
Bond, M. J. G., Bolhuis, K., Loosveld, O. J. L., de Groot, J. W. B., Droogendijk, H. J., Helgason, H. H., Hendriks, M. P., Klaase, J. M., Geert Kazemier, M., Liem, M. S. L., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.5174 · Cited by 41
Manca, P., Corallo, S., Lonardi, S., Fucà, G., Busico, A., Leone, A. G., Corti, F., Antoniotti, C., Procaccio, L., Smiroldo, V., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01591-8 · Cited by 38
Self-citationHubbard, J. M., Tőke, E. R., Moretto, R., Graham, R. P., Youssoufian, H., Lőrincz, O., Molnár, L., Csiszovszki, Z., Mitchell, J. L., Wessling, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0112 · Cited by 36
Self-citationAvallone, A., Piccirillo, M. C., Nasti, G., Rosati, G., Carlomagno, C., Gennaro, E. D., Romano, C., Tatangelo, F., Granata, V., Cassata, A., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.18475 · Cited by 37
Self-citationWensink, G. E., Bond, M. J. G., Küçükköse, E., May, A. M., Vink, G. R., Koopman, M., Kranenburg, O., & Roodhart, J. M. L. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102174 · Cited by 35
Advances in immunotherapy for MMR proficient colorectal cancer
Lote, H., Starling, N., Pihlak, R., & Gerlinger, M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102480 · Cited by 36
Antoniotti, C., Korn, W. M., Marmorino, F., Rossini, D., Lonardi, S., Masi, G., Randon, G., Conca, V., Boccaccino, A., Tomasello, G., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.06.037 · Cited by 33
Self-citationFolprecht, G., Martinelli, E., Mazard, T., Modest, D. P., Tsuji, A., Esser, R., Cremolini, C., & Falcone, A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102301 · Cited by 31
Self-citationCombinatorial Immunotherapies for Metastatic Colorectal Cancer
Janssen, E., Subtil, B., Ortiz, F. D. L. J., Verheul, H. M. W., & Tauriello, D. V. F. (2020) · Cancers · doi:10.3390/cancers12071875 · Cited by 31
Mazzoli, G., Cohen, R., Lonardi, S., Corti, F., Élez, E., Fakih, M., Jayachandran, P., Colle, R., Shah, A. T., Salati, M., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.05.044 · Cited by 32
Self-citationZhao, Y., Wang, C., & Goel, A. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab027 · Cited by 30
EGFRAmplification in Metastatic Colorectal Cancer
Randon, G., Yaeger, R. D., Hechtman, J. F., Manca, P., Fucà, G., Walch, H. S., Lee, J., Élez, E., Seligmann, J. F., Mussolin, B., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab069 · Cited by 31
Self-citationCare Patterns and Overall Survival in Patients With Early-Onset Metastatic Colorectal Cancer
Kanter, K. N., Fish, M., Mauri, G., Horick, N., Allen, J. N., Blaszkowsky, L. S., Clark, J. W., Ryan, D. P., Nipp, R. D., Giantonio, B. J., et al. (2021) · JCO Oncology Practice · doi:10.1200/op.20.01010 · Cited by 28
Emerging Therapeutic Agents for Colorectal Cancer
Nalli, M., Puxeddu, M., Regina, G. L., Gianni, S., & Silvestri, R. (2021) · Molecules · doi:10.3390/molecules26247463 · Cited by 28
Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers
Ros, J., Rodríguez-Castells, M., Gonzalez, N. S., Baraibar, I., Salvà, F., Tabernero, J. M., & Élez, E. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2236794 · Cited by 29
Total Neoadjuvant Treatment for Locally Advanced Rectal Cancer Patients: Where Do We Stand?
Daprà, V., Airoldi, M., Bartolini, M., Fazio, R., Mondello, G., Tronconi, M. C., Prete, M. G., D’Agostino, G. R., Foppa, C., Spinelli, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512159 · Cited by 28
Song, Y., Mao, Q., Zhou, M., Liu, C.-J., Kong, L., & Hu, T. (2024) · BMC Gastroenterology · doi:10.1186/s12876-024-03134-w · Cited by 29
BRAF-mutated colorectal adenocarcinomas: Pathological heterogeneity and clinical implications
Angerilli, V., Sabella, G., Centonze, G., Lonardi, S., Bergamo, F., Mangogna, A., Pietrantonio, F., Fassan, M., & Milione, M. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103647 · Cited by 27
Self-citationIsmail, N. I., Othman, I., Abas, F., Lajis, N. H., & Naidu, R. (2020) · Molecules · doi:10.3390/molecules25173798 · Cited by 26
Predicting early extrahepatic recurrence after local treatment of colorectal liver metastases
Wensink, G. E., Bolhuis, K., Elferink, M. A. G., Fijneman, R. J. A., Kranenburg, O., Rinkes, I. H. M. B., Koopman, M., Swijnenburg, R., Vink, G. R., Hagendoorn, J., et al. (2023) · British journal of surgery · doi:10.1093/bjs/znac461 · Cited by 25
Moretto, R., Germani, M. M., Giordano, M., Conca, V., Proietti, A., Niccoli, C., Pietrantonio, F., Lonardi, S., Tamburini, E., Zaniboni, A., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02180-7 · Cited by 25
Self-citationMoretto, R., Rossini, D., Zucchelli, G., Lonardi, S., Bergamo, F., Santini, D., Cupini, S., Tomasello, G., Caponnetto, S., Zaniboni, A., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.08.009 · Cited by 24
Self-citationRossini, D., Germani, M. M., Lonardi, S., Pietrantonio, F., Dell’Aquila, E., Borelli, B., Allegrini, G., Maddalena, G., Randon, G., Marmorino, F., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.04.019 · Cited by 25
Self-citationTian, M., Fan, D., Liu, Z., Mu, X., Tao, Q., Yu, C., & Zhang, S. (2022) · Advanced Materials · doi:10.1002/adma.202205299 · Cited by 23
Assénat, E., de la Fouchardière, C., Portales, F., Ychou, M., Debourdeau, A., Desseigne, F., Iltache, S., Fiess, C., Mollévi, C., & Mazard, T. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100318 · Cited by 22
Germani, M. M., & Moretto, R. (2021) · Cancers · doi:10.3390/cancers14010052 · Cited by 21
Self-citationSunakawa, Y., Satake, H., Usher, J. L., Jaimes, Y. S., Miyamoto, Y., Nakamura, M., Kataoka, M., Shiozawa, M., Takagane, A., Terazawa, T., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100512 · Cited by 22
Targeting BRAF V600E in metastatic colorectal cancer: where are we today?
Motta, R., Arnao, V. Y., Ballena, S. V. L., Macha, C. A., Lezama, M. S., Román, C. P., Beltran, P. M., & Torrejon, A. F. (2022) · ecancermedicalscience · doi:10.3332/ecancer.2022.1489 · Cited by 23
Updates on the Management of Colorectal Cancer in Older Adults
O'Donnell, C., Hubbard, J. M., & Jin, Z. (2024) · Cancers · doi:10.3390/cancers16101820 · Cited by 28
Wang, Z., Qin, B., Ye, C.-Y., Wang, M., Yuan, L., Dai, W.-P., Li, S., Liu, K., Qin, W., Jiao, X., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2021.12.028 · Cited by 21
Genetic, Epidemiological, Clinical, and Therapeutic Trajectories in Colon and Rectal Cancers
Capuozzo, M., Picone, C., Sabbatino, F., Santorsola, M., Caraglia, F., Iervolino, D., Sirica, R., Gualillo, O., Mauro, G. D., Castiello, R., et al. (2025) · Cancers · doi:10.3390/cancers17213438 · Cited by 24
Serum CCL7 Is a Novel Prognostic Biomarker of Metastatic Colorectal Cancer
Chidimatsu, H., Tsunedomi, R., Nakagami, Y., Xu, M. Q., Nakajima, M., Nakashima-Nakasuga, C., Tomochika, S., Yoshida, S., Suzuki, N., Watanabe, Y., et al. (2022) · Anticancer Research · doi:10.21873/anticanres.16139 · Cited by 20
Real‐world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer
Xu, T., Li, J., Wang, Z., Zhang, X., Zhou, J., Lu, Z., Shen, L., & Wang, X. (2023) · Cancer Medicine · doi:10.1002/cam4.5783 · Cited by 20
Kim, H. P., Navarro, V., Zacks, S., Odin, J. A., Kleiner, D. E., & Hayashi, P. H. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.09.038 · Cited by 20
Sugumar, K., Stitzel, H. J., Wu, V., Bajor, D. J., Chakrabarti, S., Conces, M. L., Henke, L. E., Lumish, M. A., Mahipal, A., Mohamed, A., et al. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-15187-y · Cited by 19
Zhang, Z., Li, Y., Wang, H., Xu, W., Wang, C., Ma, H., Zhong, F., Ou, J., Luo, Z.-H., Luo, H.-B., et al. (2024) · Journal of Natural Products · doi:10.1021/acs.jnatprod.4c00154 · Cited by 19
Moretto, R., Rossini, D., Conca, V., Lonardi, S., Rasola, C., Antoniotti, C., Santini, D., Marmorino, F., Tomasello, G., Borelli, B., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01483-x · Cited by 20
Self-citationNapolitano, S., Ciardiello, D., Cioli, E., Martinelli, E., Troiani, T., Zampino, M. G., Fazio, N., Vita, F. D., Ciardiello, F., & Martini, G. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102905 · Cited by 19
Self-citationSonbol, M. B., Siddiqi, R. L., Usón, P. L. S., Pathak, S., Firwana, B., Botrus, G., Almader‐Douglas, D., Ahn, D. H., Borad, M. J., Starr, J. S., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac212 · Cited by 18
Carconi, C., Cerreti, M., Roberto, M., Arrivi, G., D’Ambrosio, G., Felice, F. D., Civita, M. A. D., Iafrate, F., Lucatelli, P., Magliocca, F. M., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103990 · Cited by 19
Self-citationThe Role of BRAF in Metastatic Colorectal Carcinoma–Past, Present, and Future
Djanani, A. M., Eller, S., Öfner, D., Troppmair, J., & Maglione, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239001 · Cited by 18
Pietrantonio, F., Fucà, G., Rossini, D., Schmoll, H., Bendell, J. C., Morano, F., Antoniotti, C., Corallo, S., Borelli, B., Raimondi, A., et al. (2020) · The Oncologist · doi:10.1002/onco.13642 · Cited by 18
Self-citationLai, E., Cascinu, S., & Scartozzi, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.637823 · Cited by 19
Antoniotti, C., Germani, M. M., Rossini, D., Lonardi, S., Pietrantonio, F., Santini, D., Marmorino, F., Allegrini, G., Daniel, F., Raimondi, A., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.02.031 · Cited by 18
Self-citationPietrantonio, F., Morano, F., Niger, M., Corallo, S., Antista, M., Raimondi, A., Prisciandaro, M., Pagani, F., Prinzi, N., Nichetti, F., et al. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.05.004 · Cited by 17
Self-citationRossini, D., Lonardi, S., Antoniotti, C., Santini, D., Tomasello, G., Ermacora, P., Germani, M. M., Bergamo, F., Ricci, V., Caponnetto, S., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01089-9 · Cited by 18
Self-citationGiordano, G., Parcesepe, P., Bruno, G., Piscazzi, A., Lizzi, V., Remo, A., Pancione, M., D'Andrea, M. R., Santis, E. D., Coppola, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147717 · Cited by 19
Borelli, B., Fontana, E., Giordano, M., Antoniotti, C., Lonardi, S., Bergamo, F., Pietrantonio, F., Morano, F., Tamburini, E., Boccaccino, A., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100073 · Cited by 17
Self-citationLi, X., Hu, W., Sun, H., & Gou, H. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-020-10069-5 · Cited by 16
Metadata
- Authors
- Cremolini, C., Antoniotti, C., Rossini, D., Lonardi, S., Loupakis, F., Pietrantonio, F., Bordonaro, R., Latiano, T. P., Tamburini, E., Santini, D., Passardi, A., Marmorino, F., Grande, R., Aprile, G., Zaniboni, A., Murgioni, S., Granetto, C., Buonadonna, A., Moretto, R., Corallo, S., Cordio, S., Antonuzzo, L., Tomasello, G., Masi, G., Ronzoni, M., Di Donato, S., Carlomagno, C., Clavarezza, M., Ritorto, G., Mambrini, A., Roselli, M., Cupini, S., Mammoliti, S., Fenocchio, E., Corgna, E., Zagonel, V., Fontanini, G., Ugolini, C., Boni, L., Falcone, A., Falcone, A., Lonardi, S., De Braud, F. G. M., Bordonaro, R., Maiello, E., Tamburini, E., Santini, D., Frassineti, G. L., Gamucci, T., Aprile, G., Zaniboni, A., Granetto, C., Buonadonna, A., Di Costanzo, F., Tomasello, G., Gianni, L., Di Donato, S., Carlomagno, C., Clavarezza, M., Racca, P., Mambrini, A., Roselli, M., Allegrini, G., Sobrero, A., Aglietta, M., Corgna, E., Cortesi, E., Corsi, D. C., Ballestrero, A., Bonetti, A., Di Clemente, F., Ruggeri, E., Ciardiello, F., Benasso, M., Vitello, S., Cinieri, S., Mosconi, S., Silvestris, N., Frassoldati, A., Cupini, S., Bertolini, A., Tortora, G., Bengala, C., Ferrari, D., Ardizzoia, A., Milandri, C., Chiara, S., Romano, G., Miraglia, S., Scaltriti, L., Pucci, F., Blasi, L., Brugnatelli, S., Fioretto, L., Ribecco, A. S., Longarini, R., Frisinghelli, M., & Banzi, M.
- Affiliations
- University of Pisa (IT)
- University of Milan (IT)
- Casa Sollievo della Sofferenza (IT)
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Ospedale Garibaldi (IT)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- IRCCS Ospedale San Raffaele (IT)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Ospedale di Livorno (IT)
- Ospedale Policlinico San Martino (IT)
- Candiolo Cancer Institute (IT)
- Azienda Ospedaliera Universitaria Pisana (IT)
- Fondazione Poliambulanza Istituto Ospedaliero (IT)
- Federico II University Hospital (IT)
- ORCID
- Cremolini, Chiara
- Antoniotti, Carlotta
- Rossini, Daniele
- Loupakis, Fotios
- Pietrantonio, Filippo
- Latiano, Tiziana Pia
- Passardi, Alessandro
- Marmorino, Federica
- Murgioni, Sabina
- Moretto, Roberto
- Corallo, Salvatore
- Antonuzzo, Lorenzo
- Masi, Gianluca
- Ronzoni, Monica
- Mammoliti, Serafina
- Fenocchio, Elisabetta
- Zagonel, Vittorina
- Fontanini, Gabriella
- Ugolini, Clara
- Boni, Luca
- Maiello, Evaristo
- Frassineti, Giovanni Luca
- Sobrero, Alberto
- Aglietta, Massimo
- Cortesi, Enrico
- Corsi, Domenico Cristiano
- Ballestrero, Alberto
- Bonetti, Andrea
- Ruggeri, Enzo
- Ciardiello, Fortunato
- Vitello, Stefano
- Cinieri, Saverio
- Mosconi, Stefania
- Silvestris, Nicola
- Frassoldati, Antonio
- Tortora, Giampaolo
- Ferrari, Daris
- Blasi, Livio
- Brugnatelli, Silvia
- Fioretto, Luisa
- Banzi, Maria
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 21
- Issue
- 4
- Pages
- 497-507
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W3009139795
- Cited by
- 334
- References
- 39
- Citations by year
- 2026: 35 · 2025: 45 · 2024: 50 · 2023: 53 · 2022: 53 · 2021: 67 · 2020: 31
- FWCI
- 18.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.thelancet.com
- Licence
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion, cc-by-nc-nd)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion, other-oa)
- Funders
- F. Hoffmann-La Roche
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Keywords
- metastatic colorectal cancer, FOLFOXIRI, FOLFIRI, mFOLFOX6, bevacizumab, oxaliplatin, irinotecan, 5-fluorouracil, leucovorin, first-line chemotherapy, sequential chemotherapy
- MeSH terms
- Bevacizumab, Antineoplastic Agents, Immunological, Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Neoplasm Metastasis, Organoplatinum Compounds, Colorectal Neoplasms, Disease Progression, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
